Ascendis Pharma A/S (ASND)

Ascendis Pharma Statistics

Total Valuation

Ascendis Pharma has a market cap or net worth of $9.26 billion. The enterprise value is $9.56 billion.

Market Cap	9.26B
Enterprise Value	9.56B

Important Dates

The next estimated earnings date is Thursday, May 1, 2025, after market close.

Earnings Date	May 1, 2025
Ex-Dividend Date	n/a

Share Statistics

Ascendis Pharma has 59.84 million shares outstanding. The number of shares has increased by 2.85% in one year.

Current Share Class	n/a
Shares Outstanding	59.84M
Shares Change (YoY)	+2.85%
Shares Change (QoQ)	+3.91%
Owned by Insiders (%)	0.79%
Owned by Institutions (%)	84.09%
Float	59.37M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23.79
Forward PS	16.06
PB Ratio	-84.58
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	25.40
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.17

Current Ratio	1.17
Quick Ratio	0.81
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-4.26

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-17.38%
Return on Invested Capital (ROIC)	-27.89%
Return on Capital Employed (ROCE)	-102.63%
Revenue Per Employee	$370,186
Profits Per Employee	-$384,889
Employee Count	1,017
Asset Turnover	0.36
Inventory Turnover	0.18

Taxes

In the past 12 months, Ascendis Pharma has paid $5.01 million in taxes.

Income Tax	5.01M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.20% in the last 52 weeks. The beta is 0.61, so Ascendis Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.61
52-Week Price Change	+4.20%
50-Day Moving Average	143.90
200-Day Moving Average	135.79
Relative Strength Index (RSI)	50.47
Average Volume (20 Days)	432,720

Short Selling Information

Short Interest	4.38M
Short Previous Month	3.98M
Short % of Shares Out	8.78%
Short % of Float	n/a
Short Ratio (days to cover)	8.89

Income Statement

In the last 12 months, Ascendis Pharma had revenue of $376.48 million and -$391.43 million in losses. Loss per share was -$6.76.

Revenue	376.48M
Gross Profit	330.66M
Operating Income	-288.60M
Pretax Income	-539.03M
Net Income	-391.43M
EBITDA	-283.50M
EBIT	-288.60M
Loss Per Share	-$6.76

Balance Sheet

The company has $579.30 million in cash and $886.86 million in debt, giving a net cash position of -$307.56 million or -$5.14 per share.

Cash & Cash Equivalents	579.30M
Total Debt	886.86M
Net Cash	-307.56M
Net Cash Per Share	-$5.14
Equity (Book Value)	-109.44M
Book Value Per Share	-1.83
Working Capital	158.40M

Cash Flow

In the last 12 months, operating cash flow was -$317.01 million and capital expenditures -$1.48 million, giving a free cash flow of -$332.80 million.

Operating Cash Flow	-317.01M
Capital Expenditures	-1.48M
Free Cash Flow	-332.80M
FCF Per Share	-$5.56

Margins

Gross margin is 87.83%, with operating and profit margins of -76.66% and -103.97%.

Gross Margin	87.83%
Operating Margin	-76.66%
Pretax Margin	-102.64%
Profit Margin	-103.97%
EBITDA Margin	-75.30%
EBIT Margin	-76.66%
FCF Margin	n/a

Dividends & Yields

Ascendis Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.85%
Shareholder Yield	n/a
Earnings Yield	-4.23%
FCF Yield	-3.60%

Analyst Forecast

The average price target for Ascendis Pharma is $201.79, which is 30.46% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$201.79
Price Target Difference	30.46%
Analyst Consensus	Strong Buy
Analyst Count	14
Revenue Growth Forecast (5Y)	46.68%
EPS Growth Forecast (5Y)	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Ascendis Pharma has an Altman Z-Score of 0.04 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.04
Piotroski F-Score	4